Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Folks who take one of the popular GLP-1 weight-loss meds might end up with a cancelled endoscopy or colonoscopy New research ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

A new study published in the journal JAMA Network Open found that food left in the stomach or stool left in the bowel can ...

Mathur's team published its findings Oct. 1 in the journal JAMA Network Open. As the researchers noted, prior studies have suggested that people taking GLP-1 ... one of the weight-loss treatments ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.